ZNF560

Summary

ZNF560 (zinc finger protein 560, HGNC:26484) is a protein-coding gene on chromosome 19p13.2, encoding Zinc finger protein 560 (Q96MR9). May be involved in transcriptional regulation.

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II transcription regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be active in nucleus.

Source: NCBI Gene 147741 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 134 total
• MANE Select transcript: NM_152476

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26484
Approved symbol	ZNF560
Name	zinc finger protein 560
Location	19p13.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ31986
Ensembl gene	ENSG00000198028
Ensembl biotype	protein_coding
Entrez	147741

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 1 protein_coding, 1 retained_intron

ENST00000301480, ENST00000585974

RefSeq mRNA: 2 — MANE Select: NM_152476 NM_001351678, NM_152476

CCDS: CCDS12214

Canonical transcript exons

ENST00000301480 — 10 exons

Exon	Start	End
ENSE00001117061	9470392	9470518
ENSE00001117063	9474199	9474325
ENSE00001117068	9469630	9469710
ENSE00001117071	9471296	9471378
ENSE00001136484	9498128	9498215
ENSE00001136490	9498538	9498616
ENSE00001136502	9475284	9475369
ENSE00001412956	9466355	9468334
ENSE00001780373	9473179	9473259
ENSE00003650186	9469105	9469187

Expression profiles

Bgee: expression breadth broad, 47 present calls, max score 83.14.

FANTOM5 (CAGE): breadth broad, TPM avg 0.6844 / max 51.5336, expressed in 241 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
179006	0.5756	223
179005	0.1088	47

Top tissues by expression

192 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.14	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	77.98	gold quality
right testis	UBERON:0004534	75.37	gold quality
left testis	UBERON:0004533	74.25	gold quality
testis	UBERON:0000473	72.33	gold quality
stromal cell of endometrium	CL:0002255	68.20	gold quality
secondary oocyte	CL:0000655	61.19	silver quality
cortical plate	UBERON:0005343	56.48	gold quality
ventricular zone	UBERON:0003053	56.12	gold quality
ganglionic eminence	UBERON:0004023	55.96	gold quality
placenta	UBERON:0001987	45.91	gold quality
oocyte	CL:0000023	43.93	gold quality
lower esophagus mucosa	UBERON:0035834	43.55	silver quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	43.37	gold quality
granulocyte	CL:0000094	42.89	silver quality
vastus lateralis	UBERON:0001379	41.41	gold quality
quadriceps femoris	UBERON:0001377	41.37	gold quality
superficial temporal artery	UBERON:0001614	41.33	gold quality
palpebral conjunctiva	UBERON:0001812	41.10	gold quality
mucosa of paranasal sinus	UBERON:0005030	40.98	gold quality
amniotic fluid	UBERON:0000173	40.69	gold quality
jejunal mucosa	UBERON:0000399	40.59	gold quality
biceps brachii	UBERON:0001507	40.57	gold quality
epithelium of nasopharynx	UBERON:0001951	40.45	gold quality
myocardium	UBERON:0002349	40.45	gold quality
gingival epithelium	UBERON:0001949	40.43	gold quality
germinal epithelium of ovary	UBERON:0001304	40.33	gold quality
esophagus squamous epithelium	UBERON:0006920	40.29	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	40.27	gold quality
jejunum	UBERON:0002115	40.18	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.08

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

15 targeting ZNF560, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-4302	99.89	67.94	1187
HSA-MIR-139-5P	99.80	69.50	1399
HSA-MIR-4255	99.72	67.70	1541
HSA-MIR-3685	99.62	68.83	1621
HSA-MIR-3120-3P	99.54	70.28	2669
HSA-MIR-3915	99.45	68.49	1905
HSA-MIR-4666A-5P	99.41	69.72	1887
HSA-MIR-1253	99.12	67.08	1688
HSA-MIR-519A-2-5P	98.78	71.74	1401
HSA-MIR-520B-5P	98.78	71.74	1401
HSA-MIR-4684-5P	98.29	67.99	1650
HSA-MIR-12116	97.94	68.91	595

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zfp78	ENSMUSG00000055150
rattus_norvegicus		ENSRNOG00000083797
drosophila_melanogaster	CG2712	FBGN0024975
drosophila_melanogaster	Phs	FBGN0036522
drosophila_melanogaster	CG3281	FBGN0260741

Paralogs (62): ZNF582 (ENSG00000018869), ZNF264 (ENSG00000083844), ZNF343 (ENSG00000088876), ZNF684 (ENSG00000117010), ZNF133 (ENSG00000125846), ZNF557 (ENSG00000130544), ZNF337 (ENSG00000130684), ZNF20 (ENSG00000132010), ZFP37 (ENSG00000136866), ZNF614 (ENSG00000142556), KRBOX4 (ENSG00000147121), ZNF599 (ENSG00000153896), ZNF19 (ENSG00000157429), ZNF589 (ENSG00000164048), PRDM9 (ENSG00000164256), ZNF180 (ENSG00000167384), ZNF558 (ENSG00000167785), ZNF35 (ENSG00000169981), ZNF778 (ENSG00000170100), ZNF439 (ENSG00000171291), ZNF440 (ENSG00000171295), ZNF556 (ENSG00000172000), ZNF554 (ENSG00000172006), ZNF596 (ENSG00000172748), ZNF80 (ENSG00000174255), ZNF266 (ENSG00000174652), ZNF25 (ENSG00000175395), ZNF77 (ENSG00000175691), ZNF169 (ENSG00000175787), ZNF404 (ENSG00000176222), ZNF491 (ENSG00000177599), ZNF620 (ENSG00000177842), ZNF619 (ENSG00000177873), ZNF875 (ENSG00000181666), ZNF329 (ENSG00000181894), ZFP90 (ENSG00000184939), ZNF566 (ENSG00000186017), ZNF529 (ENSG00000186020), ZNF749 (ENSG00000186230), ZNF555 (ENSG00000186300)

Protein

Protein identifiers

Zinc finger protein 560 — Q96MR9 (reviewed: Q96MR9)

All UniProt accessions (1): Q96MR9

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

RefSeq proteins (2): NP_001338607, NP_689689* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR050589	Ikaros_C2H2-ZF	Family

Pfam: PF00096, PF01352, PF13912

UniProt features (21 total): zinc finger region 15, domain 2, sequence variant 2, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96MR9-F1	64.24	0.00

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 36 (showing top): GARCIA_TARGETS_OF_FLI1_AND_DAX1_DN, chr19p13, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, FIGUEROA_AML_METHYLATION_CLUSTER_1_UP, FIGUEROA_AML_METHYLATION_CLUSTER_2_UP, FIGUEROA_AML_METHYLATION_CLUSTER_3_UP, FIGUEROA_AML_METHYLATION_CLUSTER_4_UP, FIGUEROA_AML_METHYLATION_CLUSTER_6_UP, FIGUEROA_AML_METHYLATION_CLUSTER_7_UP, GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II, GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS, RATTENBACHER_BOUND_BY_CELF1, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, MIR493_5P, GSE14308_TH1_VS_TH17_DN

GO Biological Process (3): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of transcription by RNA polymerase II (GO:0006357), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (6): RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), DNA binding (GO:0003677), sequence-specific DNA binding (GO:0043565), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase II	2
transcription by RNA polymerase II	2
negative regulation of DNA-templated transcription	1
regulation of DNA-templated transcription	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
transcription cis-regulatory region binding	1
chromatin	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity	1
transition metal ion binding	1
nucleic acid binding	1
DNA binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

310 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF560	HMX2	A2RU54	380
ZNF560	LRRIQ3	A6PVS8	349
ZNF560	DBNDD2	Q9BQY9	348
ZNF560	NALF2	O75949	323
ZNF560	SCML4	Q8N228	318
ZNF560	C19orf33	Q9GZP8	312
ZNF560	KRTAP8-1	Q8IUC2	312
ZNF560	NRIP2	Q9BQI9	310
ZNF560	CSAG1	Q6PB30	305
ZNF560	CCNQ	Q8N1B3	305
ZNF560	TMEM130	Q8N3G9	300
ZNF560	CYYR1	Q96J86	297
ZNF560	SPESP1	Q6UW49	296
ZNF560	TLCD4	Q96MV1	293
ZNF560	GAS2L1	Q99501	291

IntAct

0 interactions, top by confidence:

ESM2 similar proteins: A0JPL0, A6NK53, E7ETH6, E9Q8G5, O14628, P21506, P51508, Q09FC8, Q13360, Q2M218, Q2M3X9, Q2VY69, Q3KQV3, Q3SY52, Q4R882, Q5HY98, Q5REN4, Q5RES8, Q68DI1, Q6NX49, Q6P280, Q6PG37, Q6V9R5, Q6ZMW2, Q7Z340, Q86XU0, Q8IYI8, Q8N587, Q8N720, Q8N859, Q8NB42, Q8NDW4, Q8NEK5, Q8WXB4, Q96MR9, Q96MU6, Q96NG8, Q96NJ3, Q96SR6, Q9BR84

Diamond homologs: A0A1W2PQL4, A0JNB1, A0JPL0, A6NK53, A6QLU5, A6QPT6, A7MBI1, A8MT65, A8MUV8, A8MWA4, B2RXC5, B4DU55, B4DX44, E9PYI1, O14628, O75346, P0CH99, P0CI00, P17014, P17030, P17032, P17098, P51786, P85977, Q02386, Q06730, Q06732, Q0VAW7, Q12901, Q13360, Q14586, Q14588, Q14590, Q16587, Q2M3X9, Q2VY69, Q32M78, Q3ZCX4, Q49AA0, Q4R6J4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

134 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	118
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1597 predictions. Top by Δscore:

Variant	Effect	Δscore
19:9468333:GC:G	acceptor_gain	1.0000
19:9468334:CC:C	acceptor_gain	1.0000
19:9468335:C:CA	acceptor_loss	1.0000
19:9468335:C:CC	acceptor_gain	1.0000
19:9468336:T:A	acceptor_loss	1.0000
19:9468342:C:CT	acceptor_gain	1.0000
19:9468344:C:CT	acceptor_gain	1.0000
19:9468345:A:T	acceptor_gain	1.0000
19:9469104:CCAA:C	donor_gain	1.0000
19:9469142:T:C	donor_gain	1.0000
19:9469626:TCA:T	donor_loss	1.0000
19:9469627:CA:C	donor_loss	1.0000
19:9469628:A:AC	donor_gain	1.0000
19:9469628:A:AG	donor_loss	1.0000
19:9469629:C:CC	donor_gain	1.0000
19:9469629:C:CT	donor_loss	1.0000
19:9469707:TAAC:T	acceptor_gain	1.0000
19:9469708:AAC:A	acceptor_gain	1.0000
19:9469709:AC:A	acceptor_gain	1.0000
19:9469710:CC:C	acceptor_gain	1.0000
19:9469711:C:CC	acceptor_gain	1.0000
19:9469713:G:C	acceptor_gain	1.0000
19:9469713:G:GC	acceptor_gain	1.0000
19:9470387:CTTA:C	donor_loss	1.0000
19:9470390:A:AC	donor_gain	1.0000
19:9470390:A:T	donor_loss	1.0000
19:9470390:AC:A	donor_gain	1.0000
19:9470391:C:CG	donor_gain	1.0000
19:9470391:CC:C	donor_gain	1.0000
19:9470391:CCT:C	donor_gain	1.0000

AlphaMissense

5237 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:9467204:G:C	F581L	0.994
19:9467204:G:T	F581L	0.994
19:9467206:A:G	F581L	0.994
19:9467708:A:C	F413L	0.993
19:9467708:A:T	F413L	0.993
19:9467710:A:G	F413L	0.993
19:9467288:G:C	F553L	0.987
19:9467288:G:T	F553L	0.987
19:9467290:A:G	F553L	0.987
19:9467792:G:C	F385L	0.987
19:9467792:G:T	F385L	0.987
19:9467794:A:G	F385L	0.987
19:9467120:G:C	F609L	0.983
19:9467120:G:T	F609L	0.983
19:9467122:A:G	F609L	0.983
19:9466616:A:C	F777L	0.980
19:9466616:A:T	F777L	0.980
19:9466618:A:G	F777L	0.980
19:9467765:A:C	H394Q	0.979
19:9467765:A:T	H394Q	0.979
19:9467456:A:C	F497L	0.978
19:9467456:A:T	F497L	0.978
19:9467458:A:G	F497L	0.978
19:9467681:A:C	H422Q	0.978
19:9467681:A:T	H422Q	0.978
19:9470483:G:C	F119L	0.978
19:9470483:G:T	F119L	0.978
19:9470485:A:G	F119L	0.978
19:9467187:A:G	L587P	0.977
19:9467429:A:C	H506Q	0.977

dbSNP variants (sampled 300 via entrez): RS1000002683 (19:9469416 A>C), RS1000020831 (19:9456136 A>C), RS1000110503 (19:9475810 G>A), RS1000156887 (19:9497727 A>G), RS1000186586 (19:9496839 G>A), RS1000194164 (19:9457770 G>A,T), RS1000203338 (19:9463438 T>C,G), RS1000222117 (19:9479148 C>G,T), RS1000242385 (19:9490004 T>G), RS1000294627 (19:9490304 C>A), RS1000315752 (19:9459022 G>A), RS1000317637 (19:9463145 G>A), RS1000516620 (19:9480026 G>A), RS1000564375 (19:9459365 C>G), RS1000628734 (19:9491421 C>T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

8 total (human), top 8 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	increases expression	1
arsenite	decreases expression, increases methylation	1
bisphenol S	decreases methylation	1
Arsenic	affects methylation	1
Benzo(a)pyrene	affects methylation	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	increases expression	1
Aflatoxin B1	increases methylation	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_XW64	HEK293 eGFP-ZNF560	Transformed cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer